Gossamer Bio Q4/FY23 results: first PAH patient dosed in Phase 3 PROSERA, cash $296M into H1 2026

Gossamer Bio, Inc.

First PAH patient dosed in registrational Phase 3 PROSERA study; topline results expected Q4 2025.
Japan PMDA accepted CTN, allowing inclusion of Japanese sites without PK bridging; could support Japanese NDA.
Cash, equivalents & marketable securities $296.4M at Dec 31, 2023; expected to fund operations into H1 2026.
Net loss for FY2023: $179.8M ($1.18 per share) vs $229.4M ($2.71) in FY2022.
R&D expenses FY2023: $135.3M vs $170.9M in FY2022; G&A: $38.5M vs $47.6M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Gossamer Bio, Inc. reported financial results for the fourth quarter and year ended December 31, 2023.

Period: the fourth quarter and year ended December 31, 2023
Result: reported results

Exact text from the filing

On March 5, 2024 , Gossamer Bio, Inc. (the “Company”) issued a press release reporting its financial results for the quarter and fiscal year ended December 31, 2023.

View on SEC.gov

710 earnings releases filed in the last 30 days. Browse all earnings releases →

Gossamer Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001728117-24-000018

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.